JP2023516685A5 - - Google Patents
Info
- Publication number
- JP2023516685A5 JP2023516685A5 JP2022552807A JP2022552807A JP2023516685A5 JP 2023516685 A5 JP2023516685 A5 JP 2023516685A5 JP 2022552807 A JP2022552807 A JP 2022552807A JP 2022552807 A JP2022552807 A JP 2022552807A JP 2023516685 A5 JP2023516685 A5 JP 2023516685A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- viral vector
- vector according
- promoter
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984716P | 2020-03-03 | 2020-03-03 | |
| US62/984,716 | 2020-03-03 | ||
| PCT/US2021/020721 WO2021178571A1 (en) | 2020-03-03 | 2021-03-03 | On demand expression of exogenous factors in lymphocytes to treat hiv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516685A JP2023516685A (ja) | 2023-04-20 |
| JP2023516685A5 true JP2023516685A5 (cg-RX-API-DMAC7.html) | 2024-03-04 |
Family
ID=77614437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552807A Pending JP2023516685A (ja) | 2020-03-03 | 2021-03-03 | Hivを処置するためのリンパ球における外因性因子のオンデマンド発現 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240279678A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114439A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023516685A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220150320A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115551532A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021232603A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017678A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170630A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296096A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178571A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| US12559769B2 (en) | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| EP3876952A4 (en) | 2018-11-05 | 2022-08-24 | American Gene Technologies International Inc. | VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA |
| US20230140346A1 (en) * | 2020-05-19 | 2023-05-04 | Ixaka France | Promoter Sequences for In Vitro and In Vivo Expression of Gene Therapy Products in CD3+ Cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4645697A (en) * | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| US7368114B2 (en) * | 2001-10-25 | 2008-05-06 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion protein including of CD4 |
| US7811580B2 (en) * | 2002-05-07 | 2010-10-12 | Novartis Vaccines & Diagnostics, Inc. | Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes |
| US9719106B2 (en) * | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| JP6991131B2 (ja) * | 2015-09-22 | 2022-02-03 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Hiv感染症を処置するためにt細胞を再度方向付ける方法 |
| WO2017213697A1 (en) * | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| CA3028982A1 (en) * | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| KR20230093381A (ko) * | 2017-01-09 | 2023-06-27 | 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 | 예비-면역화 단계가 없는 hiv 면역요법 |
| US12559769B2 (en) * | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| EP3773622A4 (en) * | 2018-03-27 | 2021-12-01 | American Gene Technologies International Inc. | METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES |
| KR20210031898A (ko) * | 2018-07-13 | 2021-03-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 전염병을 치료하기 위한 공동수용체 시스템 |
-
2021
- 2021-03-03 AU AU2021232603A patent/AU2021232603A1/en active Pending
- 2021-03-03 BR BR112022017678A patent/BR112022017678A2/pt not_active IP Right Cessation
- 2021-03-03 IL IL296096A patent/IL296096A/en unknown
- 2021-03-03 EP EP21764102.6A patent/EP4114439A4/en active Pending
- 2021-03-03 US US17/908,509 patent/US20240279678A1/en active Pending
- 2021-03-03 KR KR1020227033216A patent/KR20220150320A/ko not_active Withdrawn
- 2021-03-03 CA CA3170630A patent/CA3170630A1/en active Pending
- 2021-03-03 JP JP2022552807A patent/JP2023516685A/ja active Pending
- 2021-03-03 WO PCT/US2021/020721 patent/WO2021178571A1/en not_active Ceased
- 2021-03-03 CN CN202180032693.0A patent/CN115551532A/zh active Pending
-
2023
- 2023-07-28 US US18/227,775 patent/US20240141374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11612649B2 (en) | HIV pre-immunization and immunotherapy | |
| Bunnell et al. | Gene therapy for infectious diseases | |
| US20250121050A1 (en) | Methods of producing cells resistant to hiv infection | |
| CN110462029B (zh) | 无预先免疫步骤的hiv免疫疗法 | |
| JP2019527055A5 (cg-RX-API-DMAC7.html) | ||
| US20240115604A1 (en) | Methods of manufacturing genetically-modified lymphocytes | |
| US20240141374A1 (en) | On demand expression of exogenous factors in lymphocytes | |
| von Gegerfelt et al. | Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization | |
| Buffa et al. | A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice | |
| Lori et al. | Gene therapy approaches to HIV infection | |
| RU2697781C2 (ru) | Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека | |
| Moriya et al. | Abrogation of AIDS vaccine-induced cytotoxic T-lymphocyte efficacy in vivo due to a change in viral epitope flanking sequences | |
| Warner et al. | Human immunodeficiency virus immunotherapy using a retroviral vector | |
| WO2025064901A2 (en) | Hiv vaccination and immunotherapy | |
| Fujii et al. | A potential live vector, foamy virus, directed intra-cellular expression of ovine interferon-τ exhibited the resistance to HIV infection | |
| WO2025050047A1 (en) | Combination immunotherapy and antiviral treatment |